Utilization of Atezolizumab Plus Bevacizumab as Subsequent-line Therapy in Patients with Unresectable Hepatocellular Carcinoma: Abstracts of the 15th Biennial Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), 6-9 June 2023, Lyon, France.

A. Abudayyeh, A. Esmail, A. Kaseb, J. Xu, G. Umoru, K. Abboud, M. Abdelrahim

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	S321-S322
Journal	HPB
Volume	25
DOIs	https://doi.org/10.1016/j.hpb.2023.07.253
State	Published - Jan 1 2023

Divisions

Medical Oncology

Access to Document

10.1016/j.hpb.2023.07.253

https://www.sciencedirect.com/science/article/pii/S1365182X23011486

Cite this

Abudayyeh, A., Esmail, A., Kaseb, A., Xu, J., Umoru, G., Abboud, K., & Abdelrahim, M. (2023). Utilization of Atezolizumab Plus Bevacizumab as Subsequent-line Therapy in Patients with Unresectable Hepatocellular Carcinoma: Abstracts of the 15th Biennial Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), 6-9 June 2023, Lyon, France. HPB, 25, S321-S322. https://doi.org/10.1016/j.hpb.2023.07.253

Utilization of Atezolizumab Plus Bevacizumab as Subsequent-line Therapy in Patients with Unresectable Hepatocellular Carcinoma: Abstracts of the 15th Biennial Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), 6-9 June 2023, Lyon, France. / Abudayyeh, A.; Esmail, A.; Kaseb, A. et al.
In: HPB, Vol. 25, 01.01.2023, p. S321-S322.

Research output: Contribution to journal › Article › peer-review

Abudayyeh, A, Esmail, A, Kaseb, A, Xu, J, Umoru, G, Abboud, K & Abdelrahim, M 2023, 'Utilization of Atezolizumab Plus Bevacizumab as Subsequent-line Therapy in Patients with Unresectable Hepatocellular Carcinoma: Abstracts of the 15th Biennial Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), 6-9 June 2023, Lyon, France.', HPB, vol. 25, pp. S321-S322. https://doi.org/10.1016/j.hpb.2023.07.253

Abudayyeh A, Esmail A, Kaseb A, Xu J, Umoru G, Abboud K et al. Utilization of Atezolizumab Plus Bevacizumab as Subsequent-line Therapy in Patients with Unresectable Hepatocellular Carcinoma: Abstracts of the 15th Biennial Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), 6-9 June 2023, Lyon, France. HPB. 2023 Jan 1;25:S321-S322. doi: 10.1016/j.hpb.2023.07.253

@article{494444fe10a24441ad16e0281ca43c9e,

title = "Utilization of Atezolizumab Plus Bevacizumab as Subsequent-line Therapy in Patients with Unresectable Hepatocellular Carcinoma: Abstracts of the 15th Biennial Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), 6-9 June 2023, Lyon, France.",

author = "A. Abudayyeh and A. Esmail and A. Kaseb and J. Xu and G. Umoru and K. Abboud and M. Abdelrahim",

year = "2023",

month = jan,

day = "1",

doi = "10.1016/j.hpb.2023.07.253",

language = "English (US)",

volume = "25",

pages = "S321--S322",

journal = "HPB",

issn = "1365-182X",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Utilization of Atezolizumab Plus Bevacizumab as Subsequent-line Therapy in Patients with Unresectable Hepatocellular Carcinoma

T2 - Abstracts of the 15th Biennial Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), 6-9 June 2023, Lyon, France.

AU - Abudayyeh, A.

AU - Esmail, A.

AU - Kaseb, A.

AU - Xu, J.

AU - Umoru, G.

AU - Abboud, K.

AU - Abdelrahim, M.

PY - 2023/1/1

Y1 - 2023/1/1

U2 - 10.1016/j.hpb.2023.07.253

DO - 10.1016/j.hpb.2023.07.253

M3 - Article

SN - 1365-182X

VL - 25

SP - S321-S322

JO - HPB

JF - HPB

ER -